Yes — persistent itching with no rash can be the first sign of liver disease, often months before any jaundice. The pattern is itch on the palms and soles, worse at night, with nothing on the skin but scratch marks. A raised alkaline phosphatase on a routine liver function test is the clue. In pregnancy, itch with serum bile acids of 100 µmol/L or more needs urgent review.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- Liver itch has no primary rash. If the only thing on the skin is scratch marks, think bile, not allergy.
- The commonest liver causes are primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy, drug-induced cholestasis and a blocked bile duct. Ordinary cirrhosis from alcohol or fatty liver itches far less often.
- One blood test separates most liver itch from skin itch: alkaline phosphatase (ALP), usually with GGT. Bilirubin can be completely normal.
- EASL and AASLD recommend a stepwise ladder: treat the cause, then cholestyramine first, rifampicin second, naltrexone third, sertraline after that. Antihistamines are not on the ladder.
- In 2026 the first drug licensed specifically for PBC itch — linerixibat — was approved in the USA and UK. Its availability in India is not yet established.
- Itch that will not settle despite every drug is itself an accepted indication for liver transplantation; the itch typically disappears within a day of the new liver working.
A composite of a patient I meet several times a year. A 44-year-old school teacher from Dadar has itched for eleven months. It began on the soles of her feet, then the palms, and it is worst between midnight and three in the morning — she has taken to sleeping with a wet towel over her feet. Two dermatologists have treated her for “allergy”: antihistamines, steroid creams, a change of detergent, a change of soap. Nothing has helped, and nothing has ever appeared on her skin except the marks of her own nails. Her eyes are white. She is not jaundiced. A routine health check-up finally shows an alkaline phosphatase nearly three times the upper limit of normal with a normal bilirubin; the GGT is high too. An anti-mitochondrial antibody comes back positive. She has primary biliary cholangitis, and the itch was the liver trying to tell her for the best part of a year.
I tell this story because the delay in it is the rule, not the exception. Itch is a skin symptom, so people go to skin doctors, and skin doctors — reasonably — treat skin. But a specific kind of itch, with a specific pattern, comes from retained bile and not from the skin at all. It is called cholestatic pruritus, and once you know what it looks like you cannot unsee it.
This guide is for the person who has itched for months without an answer and has begun to wonder about the liver, and for the patient with known PBC, PSC or cholestasis who wants to know what can actually be done. It is anchored to the EASL and AASLD guidelines and the trials behind them. It is educational, not a prescription: anyone with persistent unexplained itch should be examined and tested by a doctor.
How to tell liver itch from skin itch
Start with what is not there. Allergic and dermatological itch comes with a primary lesion — hives, eczema, a scaly plaque, the burrows of scabies, the dry crazed skin of winter. Cholestatic itch has none. The skin looks normal until the patient scratches it, and then the only findings are excoriations, scratch marks and, after months, thickened or darkened patches where the scratching has been hardest. If a dermatologist has looked carefully and found nothing to treat, that absence is itself a clue.
Second, where it is. Liver itch favours the palms and the soles, often starting there before spreading to the limbs and trunk. Skin itch rarely picks the palms and soles as its first address.
Third, when. Cholestatic itch is characteristically worse in the evening and at night and is aggravated by warmth — a hot bath, a heavy blanket, a Mumbai summer. The EASL guideline on PBC specifically notes that itch triggered or worsened by heat at night responds to cool water, which is why so many of these patients have discovered the wet towel on their own.
Fourth, what else. Tiredness out of proportion to activity, dry eyes and mouth, pale stools, dark urine, and in later disease a yellow tinge to the whites of the eyes. None of these is required — many patients with liver itch have nothing but the itch — but any one of them alongside itch should push you towards a liver function test rather than another antihistamine.
Kidney itch is the other great internal cause: it belongs to advanced chronic kidney disease, is generalised rather than palm-and-sole, and travels with a raised creatinine rather than a raised ALP. The table sets the three side by side.
| Feature | Liver (cholestatic) itch | Skin / allergic itch | Kidney (uraemic) itch |
|---|---|---|---|
| Rash | None — only scratch marks | Primary lesion present: hives, eczema, scale, burrows | Usually none; dry skin common |
| Where it starts | Palms and soles, then limbs | Wherever the skin disease is | Back, arms, generalised |
| Timing | Evening and night; worse with heat | Variable; often with exposure to trigger | Often worse during or after dialysis |
| Companion signs | Fatigue, dark urine, pale stools, later jaundice | Sneezing, wheeze, known allergen | Swelling, breathlessness, anaemia |
| Key tests | ALP, GGT, bilirubin, bile acids, AMA, ultrasound/MRCP | Skin examination, allergy testing if indicated | Creatinine, eGFR, urea, phosphate |
| Does antihistamine help? | Rarely — sedation at most | Often | Rarely |
| Who treats it | Hepatologist | Dermatologist / allergist | Nephrologist |
Which liver conditions cause itching
The common thread is cholestasis — bile that is made but cannot flow properly, so its components back up into the blood. Which component actually causes the itch is still debated (bile acids, autotaxin and lysophosphatidic acid are the leading suspects), but the clinical rule is simple: the more cholestatic the disease, the more it itches. Diseases that damage liver cells without blocking bile — most alcohol-related and fatty-liver cirrhosis, most viral hepatitis — itch much less, and often not at all.
Primary biliary cholangitis (PBC) is the condition to think of first in a middle-aged woman with unexplained itch. The immune system slowly destroys the small bile ducts inside the liver. Itch and fatigue are the characteristic symptoms, though EASL is careful to point out that many patients never itch and its absence should not be used to rule the disease out. The diagnosis usually rests on a persistently raised ALP plus a positive anti-mitochondrial antibody; biopsy is rarely needed. The disease was renamed from “primary biliary cirrhosis” because most patients today are diagnosed long before cirrhosis, and with treatment many never reach it.
Primary sclerosing cholangitis (PSC) is its cousin: inflammation and scarring of the larger bile ducts, more often in men, strongly linked to ulcerative colitis. Itch is common and can be severe; the 2022 EASL guideline on sclerosing cholangitis covers its diagnosis by MRCP and its long-term risks, including bile-duct cancer.
Intrahepatic cholestasis of pregnancy (ICP) is itch in the third trimester, classically on the palms and soles at night, with raised serum bile acids. It resolves after delivery but matters enormously for the baby — more on this below.
Drug- and herb-induced cholestasis is under-recognised in India. Antibiotics such as amoxicillin-clavulanate, anti-tuberculosis drugs, oral contraceptives, anabolic steroids and a long list of Ayurvedic and herbal products can all produce a cholestatic injury that presents as itch, with or without jaundice. I reported a young bodybuilder whose anabolic steroid use led to vanishing bile duct syndrome — a severe, sometimes permanent loss of bile ducts — and was part of the nationwide study of liver injury from Tinospora cordifolia (Giloy) during the pandemic. “Natural” and “for fitness” do not mean safe for the liver. My post on drug-induced liver injury in India covers the common culprits.
Mechanical obstruction — a stone in the common bile duct, a stricture, or a tumour of the bile duct, pancreas head or ampulla — causes itch alongside jaundice, dark urine and pale stools, often with pain or weight loss. This is the group where delay costs the most: the cause is frequently fixable by ERCP or surgery, and painless jaundice with weight loss in an older person must be presumed to be a cancer until proven otherwise.
The tests your doctor will order
The first step is cheap and available in every Indian laboratory: a liver function test. In cholestatic disease the pattern is a raised alkaline phosphatase (ALP), usually with a raised GGT, out of proportion to the transaminases (ALT/AST). Bilirubin may be normal for years — the single most common reason liver itch is missed, because people and sometimes doctors equate “liver problem” with “jaundice”. ALP also rises from bone, so the GGT is what confirms the liver as the source.
Once cholestasis is confirmed, the questions are “where” and “why”. An ultrasound answers the first: dilated bile ducts point to a blockage, normal ducts to disease inside the liver. If ducts are dilated or PSC is suspected, an MRCP — an MRI of the bile ducts, no radiation, no scope — maps the biliary tree. For the “why”, anti-mitochondrial antibody (AMA) is the hallmark of PBC, with specific anti-nuclear antibody patterns (sp100, gp210) helping when AMA is negative; serum bile acids are the diagnostic test in pregnancy. A careful drug and supplement history — every herbal churna, protein powder and gym injection — is a test too, and often the most revealing one. Liver biopsy is reserved for the genuinely unclear case, and a FibroScan tells us how much scarring has already accumulated without a needle.
Treatment: the guideline ladder, step by step
Two principles come before any itch tablet. First, treat the cause: ursodeoxycholic acid for PBC, stone removal or stenting for an obstructed duct, stopping the offending drug in drug-induced cholestasis, delivery in ICP. Many patients need nothing else. Second, treat the skin: emollients for dryness, short nails, cool showers, light cotton clothing, a cool bedroom — EASL lists these as the base of the pyramid, and they cost nothing.
When the itch persists, both the EASL (2017) and AASLD (2018, updated 2021) PBC guidelines set out a stepwise ladder, and the same ladder is used across cholestatic diseases:
Step 1 — cholestyramine. A powder that binds bile acids in the gut so they are excreted rather than reabsorbed. EASL recommends it as first-line “given its favourable safety profile, despite its limitations” — the limitations being bloating, constipation, an unpleasant texture, and the need to separate it by several hours from every other medicine, including ursodeoxycholic acid, because it binds those too.
Step 2 — rifampicin. Better known as a tuberculosis drug, it relieves cholestatic itch through a quite different mechanism and has randomised-trial evidence behind it. It is EASL’s second-line choice. It can injure the liver and cause haemolysis, so the guideline asks for liver tests to be rechecked at 6 and 12 weeks after starting and after any dose change, and the drug stopped if they deteriorate. It also turns urine and tears orange — patients should be warned.
Step 3 — naltrexone. An opioid antagonist, reflecting the role of the brain’s own opioid system in cholestatic itch. It is started low to avoid a withdrawal-like reaction in the first days, and long-term tolerability can be a problem.
Step 4 — sertraline (an antidepressant used here for its effect on itch pathways) and gabapentin, used empirically in patients who have failed the agents above; EASL notes only a single small placebo-controlled study for sertraline.
Two things are not on the ladder: antihistamines, whose only benefit is sedation, and steroid creams, which treat inflammation that is not there.
Fibrates and the newer drugs
Bezafibrate is the interesting outsider. Used off-label for PBC that responds poorly to ursodeoxycholic acid, it was tested specifically for itch in the FITCH trial: 74 patients with PBC, PSC or secondary sclerosing cholangitis and moderate-to-severe itch were randomised to bezafibrate or placebo for three weeks, and 45% on bezafibrate achieved at least a halving of their itch against 11% on placebo. The 2024 EASL guideline on genetic cholestatic diseases now lists fibrates among the first-line options for cholestatic pruritus in adults. In India, where bezafibrate is inexpensive and familiar, this is a practical option — under specialist supervision, because fibrates can affect kidney function.
Two new second-line PBC drugs, seladelpar and elafibranor, were approved abroad in 2024 for their effect on liver biochemistry. Only seladelpar also improved itch significantly in its phase 3 trial; elafibranor did not reach significance on that endpoint. Neither is a licensed itch drug as such, and neither is established in India at the time of writing.
The genuine breakthrough is the IBAT inhibitors — tablets that block the transporter in the small intestine that recycles bile acids back to the liver, shrinking the bile acid pool. Two of them, odevixibat and maralixibat, have been approved abroad since 2021 for itch in rare childhood cholestatic diseases (progressive familial intrahepatic cholestasis and Alagille syndrome), and the 2024 EASL guideline recommends them there. For adults, linerixibat was tested in the GLISTEN phase 3 trial of 238 PBC patients with moderate-to-severe itch and improved itch scores significantly more than placebo over 24 weeks, at the cost of diarrhoea in six out of ten patients. In March 2026 it became the first drug ever approved by the US FDA specifically for cholestatic pruritus in PBC, with UK approval following in May 2026. Whether and when it reaches India I cannot yet say — ask your hepatologist rather than the internet.
When nothing works: the last steps
For the small group whose itch is unbearable despite every drug, specialist centres can offer salvage measures — plasmapheresis, nasobiliary drainage, ultraviolet light — all of which EASL restricts to expert units pending better evidence. And then there is the definitive answer. EASL’s PBC guideline states that pruritus that is “persistent and intractable” after therapeutic trials is one of the variant syndromes that constitutes an indication for liver transplantation, and that relief is rapid — frequently within the first 24 hours. I have seen it: people who had not slept properly for years, asleep through the night on the second post-operative day. It is one of the most gratifying outcomes in transplant medicine, and it is why a patient with refractory itch should never be told to simply live with it.
One warning sits inside that guideline. EASL notes that patients with severe itch may have an aggressive, “ductopenic” variant of PBC with a poorer prognosis, and recommends referral to an expert centre. Severe itch is not usually a sign of severe liver damage — but occasionally it is the first sign of a disease that is going to move fast, and that is a judgement for a hepatologist, not a chemist.
Itching in pregnancy: why it matters for the baby
Itch in late pregnancy is common and mostly harmless — stretching skin, dry skin, the heat. But itch on the palms and soles at night in the third trimester, with no rash, should always prompt a serum bile acid test, because it may be intrahepatic cholestasis of pregnancy. The mother is rarely in danger. The baby can be.
A 2019 individual-patient meta-analysis in The Lancet of over 5,000 pregnancies with ICP settled the question. In singleton pregnancies, stillbirth occurred in 0.13% of women whose peak bile acids stayed below 40 µmol/L, 0.28% at 40–99 µmol/L, and 3.44% once bile acids reached 100 µmol/L or more — a roughly thirty-fold increase at the top threshold. Most women with ICP sit below that line and can be reassured, provided bile acids are rechecked until delivery.
That threshold now drives obstetric care. The Society for Maternal-Fetal Medicine (2021) recommends ursodeoxycholic acid as first-line treatment for maternal symptoms, antenatal monitoring, and offering delivery at 36 weeks when bile acids are 100 µmol/L or above, with delivery between 36 and 39 weeks below that level; the RCOG’s 2022 Green-top guideline takes a similar risk-stratified approach. The practical message: itchy palms and soles after 28 weeks is a reason to call your obstetrician this week, and the bile acid test should be requested by name, because it is not part of a standard liver function panel.
Red flags: when to see a doctor promptly
Most itch is not liver disease. But see a physician — ideally with a liver function test in hand — if itch has lasted more than six weeks with no rash to explain it, is concentrated on the palms and soles, or is reliably worse at night. See one urgently, within days, if itch comes with yellowing of the eyes or skin; dark, tea-coloured urine; pale stools; unexplained weight loss; fever with right upper abdominal pain; or pregnancy. These combinations point to obstruction, infection of the bile ducts, or a cause that will not wait. My guide to the warning signs of liver damage covers the wider picture, and the other liver conditions page describes the cholestatic diseases we treat at Gleneagles.
And one plea on behalf of the patients I see too late: if you have been treated for “allergy” for months and nothing on your skin has ever been found, ask for an alkaline phosphatase. It is the cheapest test in hepatology, and the one that would have given the teacher from Dadar her answer ten months sooner.
Frequently asked questions
Can liver problems cause itching without jaundice?
Yes, very commonly. In primary biliary cholangitis and early bile-duct disease, itching often appears months or years before any yellowing, and bilirubin can be completely normal. The clue is a raised alkaline phosphatase (ALP), usually with raised GGT, on a liver function test. Waiting for jaundice is the main reason liver itch gets missed.
Why is liver itch worse at night?
Cholestatic itch characteristically peaks in the evening and at night and is aggravated by warmth — a hot bath, a heavy blanket, a warm room. The exact reason is not settled; bile acid levels, body temperature and the brain’s itch pathways all fluctuate with the day. Practically, EASL notes that cool water and a cool bedroom help, and that a strongly nocturnal, heat-sensitive itch should raise suspicion of a liver cause.
Does itching mean my liver damage is severe?
Usually not. EASL states that in PBC the severity of symptoms does not necessarily correlate with the stage of disease, and many people with advanced cirrhosis never itch at all. The exception is a small group with very severe itch who may have an aggressive “ductopenic” form of PBC; EASL recommends such patients be referred to an expert liver centre for assessment.
Can antihistamines help liver itch?
Rarely, and they are not recommended in the EASL or AASLD guidelines for cholestatic itch. Any relief comes from sedation rather than from acting on the cause. Guideline-backed treatments are cholestyramine first, then rifampicin, naltrexone and sertraline, with bezafibrate and newer drugs such as linerixibat for selected patients — all under a doctor’s supervision.
Is itching in pregnancy a liver problem?
Sometimes. Itch on the palms and soles at night in the third trimester, without a rash, may be intrahepatic cholestasis of pregnancy and needs a serum bile acid test. Most cases are mild, but bile acids of 100 µmol/L or more are linked to a substantially higher risk of stillbirth, so obstetricians monitor closely and may advise delivery at 36 weeks. Ask for the bile acid test by name.
Can liver itch be cured?
If the cause is removable — a bile-duct stone, a drug, pregnancy — the itch resolves once the cause is treated. In chronic diseases like PBC and PSC it is controlled rather than cured, using the stepwise ladder of medicines. For the few whose itch stays intractable despite every treatment, liver transplantation is an accepted indication and relieves the itch, often within 24 hours.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172. PMID 28427765. doi:10.1016/j.jhep.2017.03.022
- Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394–419. PMID 30070375. doi:10.1002/hep.30145
- Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology. 2022;75(4):1012–1013. PMID 34431119. doi:10.1002/hep.32117
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761–806. PMID 35738507. doi:10.1016/j.jhep.2022.05.011
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases. J Hepatol. 2024;81(2):303–325. PMID 38851996. doi:10.1016/j.jhep.2024.04.006
- de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160(3):734–743.e6. PMID 33031833. doi:10.1053/j.gastro.2020.10.001
- Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22–33. PMID 41173016. doi:10.1016/S2468-1253(25)00192-X
- Hoy SM. Linerixibat: first approval. Drugs. 2026;86(9):1545–1551. PMID 42301363. doi:10.1007/s40265-026-02349-3
- Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis (RESPONSE). N Engl J Med. 2024;390(9):783–794. PMID 38381664. doi:10.1056/NEJMoa2312100
- Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis (ELATIVE). N Engl J Med. 2024;390(9):795–805. PMID 37962077. doi:10.1056/NEJMoa2306185
- Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581–1592. PMID 34755627. doi:10.1016/S0140-6736(21)01256-3
- Thompson RJ, Arnell H, Artan R, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial (PEDFIC 1). Lancet Gastroenterol Hepatol. 2022;7(9):830–842. PMID 35780807. doi:10.1016/S2468-1253(22)00093-0
- Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899–909. PMID 30773280. doi:10.1016/S0140-6736(18)31877-4
- Society for Maternal-Fetal Medicine. SMFM Consult Series #53: intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol. 2021;224(2):B2–B9. PMID 33197417. doi:10.1016/j.ajog.2020.11.002
- Girling J, Knight CL, Chappell L; Royal College of Obstetricians and Gynaecologists. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43, June 2022. BJOG. 2022;129(13):e95–e114. PMID 35942656. doi:10.1111/1471-0528.17206
- Kalal C, Wagh A, Patel A, et al. A disquiet find: anabolic-androgenic steroids and vanishing bile duct syndrome. Hepatol Forum. 2020;1(3):109–111. PMID 35949722. doi:10.14744/hf.2020.2020.0021
- Kulkarni AV, Hanchanale P, Prakash V, Kalal C, et al. Tinospora cordifolia (Giloy)-induced liver injury during the COVID-19 pandemic — multicenter nationwide study from India. Hepatol Commun. 2022;6(6):1289–1300. PMID 35037744. doi:10.1002/hep4.1904
